Oxford BioMedica PLC (OXBDF)

[georgejjl]

Novartis and Oxford BioMedica's CART therapy for various solid tumors???

Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice

In summary, ErbB2 and EGFR have previously been considered as undruggable targets for CART cells. Given that dysregulation of the expression of ErbB2 and EGFR occurs frequently in multiple human carcinomas including breast, glioblastoma, lung, pancreatic, ovarian, head and neck squamous cell cancer and colon cancer, our findings have considerable clinical importance. Our strategy has the potential not only to improve the safety profile and clinical outcome of CARs directed against validated targets but also to expand the landscape to targets not previously druggable with CART cells because of on-target toxicities. More generally, our findings suggest that safer and more potent CARs can be designed by employing affinity-tuned scFvs for a variety of common carcinomas.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560113/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560113/figure/F5/

Good luck and GOD bless,

George